Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 29/11/2020
SIETES contiene 93175 citas

 
 
 1 a 20 de 141 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
2. Cita con resumen
Quinn KL, Macdonald EM, Mamdani MM, Diong C, Juurlink DN, for the Canadian Drug Safety and Effectiveness Research Network (CDSERN). Lipophilic statins and the risk of intracranial hemorrhage following ischemic stroke: a population-based study. Drug Saf 2017;40:887-93. [Ref.ID 102077]
3. Cita con resumen
Anónimo. Lipid-lowering drugs. Med Lett Drugs Ther 2016;58:133-40. [Ref.ID 100944]
4. Cita con resumen
Li DQ, Kim R, McArthur E, Fleet JL, Bailey DG, Juurlink D, Shariff SZ, Gomes T, Mamdani M, Gandhi S, Dixon S, Garg AX. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Can Med Assoc J 2015;187:174-80. [Ref.ID 98758]
5.Enlace a cita original
Tonelli M, Wanner Ch, for the Kidney disease: improving global outcomes lipid guideline development work group members. Lipid management in chronick Kidney disease: synopsis of the Kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med 2014;160:182-93. [Ref.ID 97317]
6.Tiene citas relacionadas Cita con resumen
Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013;346:14. [Ref.ID 95914]
7.Tiene citas relacionadas
Huupponen R, Viikari J. Statins and the risk of developing diabetes. BMJ 2013;346:7. [Ref.ID 95909]
8. Cita con resumen
Chung Y-H, Lee Y-C, Chang C-H, Lin M-S, Lin J-W, Lai MS. Statins of high versus low cholesterol-lowering efficacy and the development of severe renal failure. Pharmacoepidemiol Drug Saf 2013;22:583-92. [Ref.ID 95562]
9. Cita con resumen
Anónimo. Statins: risk of increased blood sugar levels and diabetes. Canada. WHO Drug Information 2013;27:16-7. [Ref.ID 95226]
10. Cita con resumen
Anónimo. Statins and HIV or hepatitis C drugs: drug safety communication - Interaction increases risk of muscle injury. U.S. Food and Drug Administration 2012:2 de marzo. [Ref.ID 92202]
11.Enlace a cita original Cita con resumen
Anónimo. Statin drugs - Drug safety communication: class labeling change. U.S. Food and Drug Administration 2012:1 de marzo. [Ref.ID 92196]
12. Cita con resumen
Chang C, Gershwin ME. Drug-induced lupus erythematosus. Incidence, management and prevention. Drug Saf 2011;34:357-74. [Ref.ID 90404]
13. Cita con resumen
Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S. Fibrate/statin initiation in warfarin users and gastrointestinal bleeding risk. The American Journal of Medicine 2010;123:151-7. [Ref.ID 88202]
14. Cita con resumen
Anónimo. Tendinopathies dues aux statines. Prescrire 2010;30:29. [Ref.ID 87604]
15. Cita con resumen
Abecia Inchaurregui LC, Abasolo Osinaga E, Etxeandia Ikobaltzeta I, Burgos Alonso N, López Picado A, Fernández Bilbao M. Evolución de la utilización de hipolipemiantes en la comunidad autónoma del País Vasco (1992-2005). Aten Farmaceutica 2009;11:361-7. [Ref.ID 87455]
16.Enlace a cita original
Strandell J, Bate A, Hägg S, Edwards IR. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol 2009;68:427-34. [Ref.ID 86710]
17.Enlace a cita original
García del Pozo J, Madurga M, de Abajo FJ. Utilización de hipolipemiantes en España, 1992-2006. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2009:. [Ref.ID 86460]
18.Tiene citas relacionadas
Phillips PS. Balancing randomized trials with anecdote. Ann Intern Med 2009;150:885-6. [Ref.ID 86262]
19.Tiene citas relacionadas
Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858-68. [Ref.ID 86261]
20.Enlace a cita original
Devold HM, Molden E, Skurtveit S, Furu K. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Br J Clin Pharmacol 2009;67:234-41. [Ref.ID 85812]
Seleccionar todas
 
 1 a 20 de 141 siguiente >>